JP2016522179A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522179A5 JP2016522179A5 JP2016509298A JP2016509298A JP2016522179A5 JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5 JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- tamoxifen
- derivative
- formula
- isomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 22
- 229960001603 tamoxifen Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- -1 tertiary amine salt Chemical class 0.000 claims 12
- 238000000034 method Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000001613 neoplastic effect Effects 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 229910052786 argon Inorganic materials 0.000 claims 2
- 229940072107 ascorbate Drugs 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- 235000021317 phosphate Nutrition 0.000 claims 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000007594 Estrogen Receptor alpha Human genes 0.000 claims 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- YWWDBCBWQNCYNR-UHFFFAOYSA-O trimethylphosphanium Chemical compound C[PH+](C)C YWWDBCBWQNCYNR-UHFFFAOYSA-O 0.000 claims 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2013-308A CZ304553B6 (cs) | 2013-04-24 | 2013-04-24 | Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2 |
| CZPV2013-308 | 2013-04-24 | ||
| CZPV2014-66 | 2014-01-29 | ||
| CZ2014-66A CZ305571B6 (cs) | 2014-01-29 | 2014-01-29 | Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2 |
| PCT/CZ2014/000035 WO2014173374A1 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522179A JP2016522179A (ja) | 2016-07-28 |
| JP2016522179A5 true JP2016522179A5 (cg-RX-API-DMAC7.html) | 2017-04-06 |
| JP6375091B2 JP6375091B2 (ja) | 2018-08-15 |
Family
ID=50677895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509298A Active JP6375091B2 (ja) | 2013-04-24 | 2014-04-07 | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9896466B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2989110B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6375091B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101764991B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105452265B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014256546B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2909994C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1120821T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2989110T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA029881B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2699099T3 (cg-RX-API-DMAC7.html) |
| GE (1) | GEP20186868B (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20181872T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE042239T2 (cg-RX-API-DMAC7.html) |
| MD (1) | MD4626C1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ713589A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2989110T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2989110T (cg-RX-API-DMAC7.html) |
| SI (1) | SI2989110T1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA116469C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014173374A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10548318B2 (en) * | 2015-07-03 | 2020-02-04 | Bayer Cropscience Aktiengesellschaft | N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide derivatives with herbicidal action |
| BR112018000088B1 (pt) * | 2015-07-03 | 2022-07-12 | Bayer Cropscience Aktiengesellschaft | Derivados de n-(1,3,4-oxadiazol-2-il)aril carboxamida com ação herbicida, seu uso, composição herbicida, e método para controle de plantas indesejadas |
| EP3368011A4 (en) * | 2016-07-12 | 2019-07-10 | Accutar Biotechnology Inc. | NOVEL CONNECTIONS AND USE THEREOF |
| AU2017312499B2 (en) | 2016-08-19 | 2023-02-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration |
| EP3330274A1 (en) * | 2016-12-01 | 2018-06-06 | Springtide Ventures s.r.o. | Compounds for treatment of senescence-related disorders |
| CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| CA3060509A1 (en) | 2017-04-21 | 2018-10-25 | Federica Sotgia | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| CA3063717C (en) | 2017-05-19 | 2021-08-24 | Lunella Biotech, Inc. | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| CA3079952A1 (en) | 2017-10-24 | 2019-05-02 | Lunella Biotech, Inc. | Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration |
| SG11202004729QA (en) | 2017-11-24 | 2020-06-29 | Lunella Biotech Inc | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
| CA3083487A1 (en) | 2017-12-01 | 2019-06-06 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| US11541120B2 (en) | 2017-12-05 | 2023-01-03 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
| CA3085375A1 (en) | 2017-12-20 | 2019-06-27 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mdivi-1 derivatives |
| EP3955935A4 (en) * | 2019-04-16 | 2023-01-18 | Lunella Biotech, Inc. | ALKYL-TPP COMPOUNDS FOR MITOCHONDRIAL TARGETING AND ANTI-CANCER TREATMENTS |
| EP3753944A1 (en) | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0551434B1 (en) * | 1990-10-01 | 1995-11-15 | The Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives and uses thereof |
| JP3635708B2 (ja) * | 1995-03-06 | 2005-04-06 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| TWI309571B (en) * | 2002-12-31 | 2009-05-11 | Ind Tech Res Inst | Delivery carrier for targeting cells haring over-expressed estrogen |
| JP4648319B2 (ja) * | 2003-08-22 | 2011-03-09 | アンティポディーン ファーマシューティカルズ インコーポレイティド | ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体 |
| CN1997403A (zh) * | 2004-07-13 | 2007-07-11 | 奥里迪斯生物医学研究及开发有限责任公司 | 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途 |
| USRE47300E1 (en) * | 2008-03-14 | 2019-03-19 | Cancure Limited | Mitochondrially delivered anti-cancer compounds |
| US20100297262A1 (en) * | 2009-04-17 | 2010-11-25 | Colby Pharmaceutical Company | Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| WO2011129837A1 (en) * | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
-
2014
- 2014-04-07 JP JP2016509298A patent/JP6375091B2/ja active Active
- 2014-04-07 CN CN201480033316.9A patent/CN105452265B/zh not_active Expired - Fee Related
- 2014-04-07 AU AU2014256546A patent/AU2014256546B2/en not_active Ceased
- 2014-04-07 MD MD20150117A patent/MD4626C1/ro not_active IP Right Cessation
- 2014-04-07 CA CA2909994A patent/CA2909994C/en active Active
- 2014-04-07 EP EP14721738.4A patent/EP2989110B1/en active Active
- 2014-04-07 HR HRP20181872TT patent/HRP20181872T1/hr unknown
- 2014-04-07 US US14/786,710 patent/US9896466B2/en active Active
- 2014-04-07 SI SI201430928T patent/SI2989110T1/sl unknown
- 2014-04-07 PT PT14721738T patent/PT2989110T/pt unknown
- 2014-04-07 DK DK14721738.4T patent/DK2989110T3/en active
- 2014-04-07 UA UAA201510642A patent/UA116469C2/uk unknown
- 2014-04-07 KR KR1020157030376A patent/KR101764991B1/ko not_active Expired - Fee Related
- 2014-04-07 ES ES14721738T patent/ES2699099T3/es active Active
- 2014-04-07 EA EA201591918A patent/EA029881B1/ru unknown
- 2014-04-07 PL PL14721738T patent/PL2989110T3/pl unknown
- 2014-04-07 HU HUE14721738A patent/HUE042239T2/hu unknown
- 2014-04-07 WO PCT/CZ2014/000035 patent/WO2014173374A1/en not_active Ceased
- 2014-04-07 NZ NZ713589A patent/NZ713589A/en not_active IP Right Cessation
-
2015
- 2015-04-07 GE GEAP201513996A patent/GEP20186868B/en unknown
-
2018
- 2018-11-06 CY CY181101155T patent/CY1120821T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522179A5 (cg-RX-API-DMAC7.html) | ||
| JP6375091B2 (ja) | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 | |
| Tang et al. | Synthesis and biological evaluation of 2, 3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2 | |
| KR20140008297A (ko) | 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체 | |
| JP2012153722A5 (cg-RX-API-DMAC7.html) | ||
| JP2013064024A5 (cg-RX-API-DMAC7.html) | ||
| JP2019519593A5 (cg-RX-API-DMAC7.html) | ||
| WO2017143059A1 (en) | Max binders as myc modulators and uses thereof | |
| NO20061319L (no) | 5-arylpyrimidiner som anticancer legemidler | |
| Zbieg et al. | Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer | |
| JP2013523867A5 (cg-RX-API-DMAC7.html) | ||
| RU2699558C2 (ru) | Средство для таргетной терапии злокачественных новообразований | |
| JP2010509306A5 (cg-RX-API-DMAC7.html) | ||
| JP6423349B2 (ja) | Ｎ−置換３，４−ビス（カテコール）ピロール化合物、その調製、及びガンの治療のためのその使用 | |
| JP2019517474A5 (cg-RX-API-DMAC7.html) | ||
| JP2020506886A5 (cg-RX-API-DMAC7.html) | ||
| Yu et al. | Discovery of potent and orally available small molecule inhibitors of the SOS1-KRAS interaction | |
| Sahu et al. | HER2 Protein | |
| CN118290386A (zh) | 7-羟基黄酮类化合物及其制备方法和应用 | |
| Corcoran | Studies toward the synthesis of radioactive tyrosine kinase inhibitors, steroidal antiestrogens, and indoles as probes of biological systems | |
| HK1216317B (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| Kluckova et al. | 424 Role of the Ubiquinone Site of Complex II in Apoptosis Induction and Malignant Transformation | |
| Fernandez-Nogueira et al. | 423 Acquisition of Resistance to Anti-Her2 Therapies Promotes a Different Microenvironment Crosstalk Capability | |
| Erturk et al. | 426 Distinct MiRNA Expression Patterns in Among Breast Tumors of Patients Carried and Non-carried Germ-line BRCA Mutations | |
| Scaiewicz et al. | THE ROLE OF THE UNFOLDED PROTEIN RESPONSE IN HEPATIC CARCINOGENESIS: 2001 |